Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 1/20 | 0.49 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 5/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | HPGD | P15428 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | PTGDR2 | Q9Y5Y4 | 4/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | CASP1 | P29466 | 1/20 | 0.43 |
| ▸ | CASP7 | P55210 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.41 |
| ▸ | FLT1 | P17948 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20487128 | 0.89 | MAPT (0.51) | PTPN11MAPTKDM4EALDH1A1HPGD | |
| SCHEMBL20487495 | 0.82 | TDP1 (0.51) | PTPN11MAPTKDM4EALDH1A1HPGD | |
| SCHEMBL20488212 | 0.81 | CA1 (0.53) | PTPN11MAPTKDM4EALDH1A1HPGD | |
| SCHEMBL23252136 | 0.81 | ALDH1A1 (0.49) | PTPN11MAPTKDM4EALDH1A1HPGD | |
| SCHEMBL22116791 | 0.80 | MAPT (0.54) | PTPN11MAPTKDM4EALDH1A1HPGD | |
| SCHEMBL29985379 | 0.80 | MAPT (0.54) | PTPN11MAPTKDM4EALDH1A1HPGD | |
| SCHEMBL20487124 | 0.80 | MAPT (0.46) | PTPN11MAPTKDM4EALDH1A1HPGD | |
| SCHEMBL1138808 | 0.80 | POLB (0.46) | PTPN11MAPTLMNAPTGDR2MAPK1 | |
| SCHEMBL20488208 | 0.79 | HPGD (0.44) | PTPN11MAPTKDM4EALDH1A1HPGD | |
| SCHEMBL20487479 | 0.78 | HDAC1 (0.60) | PTPN11MAPTKDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0947500-B1 | SULFONAMIDE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO (JP) | 2011-02-23 | — | — | EP | disclosed |
| CN-1213019-C | Sulfonamide and carboxamide derivatives and drugs containing same as active ingredient | ONO PHARMACEUTICAL CO (JP) | 2005-08-03 | — | — | CN | disclosed |
| US-6790866-B2 | SUCH AS 4-(2-PHENYLSULFONYLAMINO-5-CHLOROBENZOYLAMINO)BENZOIC ACID FOR USE AS PROSTAGLANDIN E2 ANTAGONIST OR AGONIST; FOR INHIBITION OF UTERINE CONTRACTION, ANALGESICS, ANTIDIARRHEALS, SLEEP INDUCERS, AND/OR FOR INCREASE OF VESICAL CAPACITY | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-09-14 | — | — | US | disclosed |
| US-20030060460-A1 | Such as 4-(2-phenylsulfonylamino-5-chlorobenzoylamino)benzoic acid for use as prostaglandin E2 antagonist or agonist; for inhibition of uterine contraction, analgesics, antidiarrheals, sleep inducers, and/or for increase of vesical capacity | OHUCHIDA SHUICHI (JP) | 2003-03-27 | — | — | US | disclosed |
| US-6448290-B1 | PROSTAGLANDIN E2 ANTAGONIST OR AGONIST; INHIBITION OF UTERINE CONTRACTION, ANALGESICS, ANTIDIARRHEALS, SLEEP INDUCERS, INCREASING VESICAL CAPACITY, CATHARTIC, SUPPRESSION OF GASTRIC ACID SECRETION, ANTIHYPERTENSIVE, DIURETIC AGENTS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2002-09-10 | — | — | US | disclosed |
| CN-1247529-A | Sulfonamide and carboxamide derivatives and drugs containing same as active ingredient | ONO PHARMACEUTICAL CO (JP) | 2000-03-15 | — | — | CN | disclosed |
| EP-0947500-A1 | SULFONAMIDE AND CARBOXAMIDE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 1999-10-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030060460-A1 | Such as 4-(2-phenylsulfonylamino-5-chlorobenzoylamino)benzoic acid for use as prostaglandin E2 antagonist or agonist; for inhibition of uterine contraction, analgesics, antidiarrheals, sleep inducers, and/or for increase of vesical capacity | CNR1, HCAR1, HCAR2 | ABL1 3795/4885PTPN11 2858/4885MAPT 4870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.